OR
CTKB icon

Olympiad Research’s Cytek Biosciences CTKB Stock Holding History

Olympiad Research’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,601
Closed -$127K – 265
2024
Q4 		$127K Buy
19,601
+6,617
+51% +$39.4K 0.13% 218
2024
Q3 		$71.9K Buy
+12,984
New +$73.6K 0.05% 314

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Olympiad Research's CTKB Position: Q1 2025 in Review

Olympiad Research sold out of Cytek Biosciences (CTKB) in Q1 2025, closing a stake of 19,601 shares — an estimated $127K sold.

Olympiad Research first reported a position in CTKB in Q3 2024 and held it in 2 quarters. The position peaked at $127K in Q4 2024. 160 funds tracked by Wall St. Rank hold CTKB as of Q1 2025.

  • Olympiad Research reported no remaining Cytek Biosciences position as of Q1 2025 after selling out during the quarter.
  • Olympiad Research sold 19,601 Cytek Biosciences shares in Q1 2025, an estimated $127K.
  • Olympiad Research first reported a position in Cytek Biosciences in Q3 2024 and held it in 2 quarters.
  • Olympiad Research's Cytek Biosciences position peaked at $127K in Q4 2024.
  • 160 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2025.

Based on Olympiad Research's 13F filing for Q1 2025, filed 13 May 2025.